High Use of Ozempic and Other Diabetes Drugs for Weight Loss Driving Down Clothing Sizes In New York City, According to New Study
June 17, 2024 07:00 ET | Impact Analytics
Impact Analytics announced that size small has become the most popular size for women on Manhattan’s Upper East Side.
New Weight Loss Drugs Pose Anesthesia Risk, according to Journal of American Physicians and Surgeons
June 06, 2024 13:02 ET | Association of American Physicians and Surgeons
Weight loss drugs such as semaglutide impede stomach emptying, creating a significant risk from anesthesia. The effect may last for up to two months
800 px horizontal logo.png
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024 09:00 ET | Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Costco unveils new weight loss service with healthcare partner Sesame
Wholesale Weight Loss: Sesame Unveils Specialized Care for Weight Loss with Pricing Exclusively for Costco Members
April 02, 2024 10:59 ET | Sesame
NEW YORK CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans,  today unveiled an...
CTLT Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Catalent, Inc. for Potential Securities Law Violations
February 07, 2024 09:13 ET | Wohl & Fruchter LLP
MONSEY, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Catalent, Inc. (NYSE: CTLT) (“Catalent”) has violated federal securities laws based...
CTLT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Catalent to Novo Holdings
February 05, 2024 10:04 ET | Wohl & Fruchter LLP
We are investigating the fairness of the sale of Catalent to Novo Holdings for $63.50 per share in cash.
GLP-1 receptor agonist-based compounds are the most common drug class in late stage clinical trials
Airfinity launches world’s first obesity data and analytics platform
January 24, 2024 04:57 ET | Airfinity
London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market.  ...
WeightWatchers New Logo 2023.png
WeightWatchers Unveils “Beyond Hunger: Understanding Food Noise” Report Offering Insights Into the Experience of Ongoing, Intrusive Thoughts About Food
January 16, 2024 09:16 ET | WW International Inc.
Findings of WeightWatcher's “Beyond Hunger: Understanding Food Noise” report, focus on the experience of people living with "food noise".